Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,056 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Colon Clear all
Completed No phase listed Observational Accepts healthy volunteers

Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"

NCT04144751
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Blood Sample Collection
Other
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
40 Years and older
Enrollment
23,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
194
States / cities
Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 31, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00003753
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, irinotecan hydrochloride, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 31, 2026, 2:06 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

mPATH-Cloud for Colorectal Cancer Screening

NCT06441487
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Mobile Health Decision Support, Usual care
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
45 Years to 73 Years
Enrollment
1,062 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 31, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

NCT00006366
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, irinotecan hydrochloride, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
216
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 31, 2026, 2:06 AM EDT
Withdrawn Phase 2 Interventional

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

NCT00408772
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation
Biological · Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 31, 2026, 2:06 AM EDT
Completed No phase listed Observational

Genetic Study of Familial Factors in Patients With Colon Cancer

NCT00055848
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cytogenetic analysis, gene mapping, microarray analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 70 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Goldsboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 31, 2026, 2:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

NCT07223047
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 2:06 AM EDT
Terminated Phase 1Phase 2 Interventional

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249
View directory record Official record
Conditions
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
Interventions
JDQ443, trametinib, Ribociclib, cetuximab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 2:06 AM EDT
Active, not recruiting Phase 1 Interventional

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

NCT02600949
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy, Computed Tomography, Magnetic Resonance Imaging
Drug · Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 2:06 AM EDT
Terminated Phase 3 Interventional Results available

Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer

NCT00387348
View directory record Official record
Conditions
Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
Interventions
escitalopram oxalate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 31, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

NCT02279433
View directory record Official record
Conditions
Solid Tumors
Interventions
DS6051b
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Scottsdale, Arizona • Orange, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 31, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

NCT00041652
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Breast Cancer, Breast Neoplasms
Interventions
hMN14 (labetuzumab)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 31, 2026, 2:06 AM EDT
Terminated Not applicable Interventional

A Clinical Study To Measure The Effect Of Use Of Artificial Intelligence (AI) Enabled Computer Aided Detection (CADe) Assistance Software In Detecting Colon Polyps During Standard Colonoscopy Procedures

NCT04555135
View directory record Official record
Conditions
Colon Polyp, Colon Neoplasm, Colon Adenoma
Interventions
EndoVigilant Software
Device
Lead sponsor
EndoVigilant Inc
Industry
Eligibility
45 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Mission Viejo, California • Waterbury, Connecticut • Greenbelt, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 31, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer

NCT00063960
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, irinotecan hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
10
States / cities
Little Rock, Arkansas • Lexington, Kentucky • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 31, 2026, 2:06 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Informed Choice - Compass

NCT05246839
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Brief Video, Brief Video Plus
Behavioral
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
45 Years to 70 Years
Enrollment
1,823 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
39
States / cities
Phoenix, Arizona • Los Angeles, California • Port Hueneme, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 31, 2026, 2:06 AM EDT
Recruiting Phase 1 Interventional

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

NCT05877599
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS)
Interventions
NT-175
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 2:06 AM EDT
Withdrawn Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer

NCT00025532
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
iodine I 131 monoclonal antibody CC49-deltaCH2
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 31, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional

Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00049101
View directory record Official record
Conditions
Colorectal Cancer
Interventions
erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 31, 2026, 2:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

NCT02584244
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
Interventions
LUM015, LUM 2.6 Imaging Device
Drug · Device
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 31, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

NCT02508077
View directory record Official record
Conditions
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Panitumumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Duarte, California • Lancaster, California • Rancho Cucamonga, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 31, 2026, 2:06 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

The Northern-European Initiative on Colorectal Cancer

NCT00883792
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy
Procedure
Lead sponsor
Oslo University Hospital
Other
Eligibility
55 Years to 64 Years
Enrollment
95,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2036
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 31, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

NCT03195699
View directory record Official record
Conditions
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
Interventions
TTI-101
Drug
Lead sponsor
Tvardi Therapeutics, Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 31, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma

NCT00051987
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
VELCADE TM (bortezomib) for Injection, or PS-341
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Pine Bluff, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2008 · Synced Oct 31, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib

NCT01289821
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 31, 2026, 2:06 AM EDT